The deal hands Blackstone a piece of the potential future sales of an antibody-drug conjugate that could soon challenge marketed medicines from AstraZeneca and Gilead.
Merck & Co. and Bayer’s Verquvo failed to deliver a composite cardiovascular benefit for certain patients with stable heart failure with reduced ejection fraction (HFrEF). The phase 3 Victor trial ...
Germany's Merck KGgA said on Monday it has agreed to pay Swiss biotech Debiopharm up to 900 million euros ($1.08 billion) to ...
Bayer and Merck & Co, Inc. said heart-failure drug candidate vericiguat didn't meet the primary target of a late-stage study. The German conglomerate on Monday said vericiguat in the phase 3 Victor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback